Symptom complaints of patients prescribed either oral methadone or injectable heroin

Journal of Substance Abuse Treatment

Volumn 38, Issue 4, 2010, Pages 328-337

  Dürsteler MacFarland, Kenneth M ^a,b   Fischer, Dominique A ^a   Mueller, Sandra ^a   Schmid, Otto ^a   Moldovanyi, Andreas ^b,c   Wiesbeck, Gerhard A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^c City Medical Services   (Switzerland)

Author keywords

Heroin; Maintenance treatment; Methadone; Opioid dependence; Side effects; Symptom complaints

Indexed keywords

DIAMORPHINE; METHADONE; NON PRESCRIPTION DRUG;

ABDOMINAL PAIN; ADULT; ARM DISEASE; ARTICLE; ATTENTION DISTURBANCE; ATTITUDE TO HEALTH; BLURRED VISION; BREAKTHROUGH BLEEDING; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG ABUSE; DRUG TOLERABILITY; DYSMENORRHEA; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FRACTURE; HEAD AND NECK DISEASE; HEADACHE; HEART DISEASE; HUMAN; HYPERSALIVATION; HYPOSALIVATION; INJECTION SITE CONTUSION; INJECTION SITE DISCOLORATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LEG CRAMP; LIBIDO DISORDER; LIMB DISEASE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENSTRUAL IRREGULARITY; METHADONE TREATMENT; MICTURITION DISORDER; NAUSEA; OPIATE ADDICTION; ORGASM DISORDER; PARALYSIS; PARESTHESIA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SKIN PRURITUS; SKIN REDNESS; SKIN SWELLING; SWEATING; SYMPTOM; THIRST; TOOTH DISEASE; TREATMENT DURATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; FEMALE; HEROIN; HUMANS; INJECTIONS; MALE; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; QUESTIONNAIRES;

EID: 77952241642     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.01.008     Document Type: Article

References (69)

1. Act-Info Nationale Substitutionsstatistik (Methadon): Federal Office of Public Health Available at. http://www.nasuko.ch/nms/db/index.cfm.
2. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28:321-329.
3. Ball J.C., Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcome 1991, Springer Verlag, New York.
4. Barsky A.J., Saintfort R., Rogers M.P., Borus J.F. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002, 287:622-627.
5. Bell J., Mattick R., Hay A., Chan J., Hall W. Methadone maintenance and drug-related crime. Journal of Substance Abuse 1997, 9:15-25.
6. Bent S., Padula A., Avins A.L. Brief communication: Better ways to question patients about adverse medical events: A randomized, controlled trial. Annals of Internal Medicine 2006, 144:257-261.
7. Blattler R., Dobler-Mikola A., Steffen T., Uchtenhagen A. Decreasing intravenous cocaine use in opiate users treated with prescribed heroin. Sozial-und Präventivmedizin 2002, 47:24-32.
8. Brown B.S., Benn G.J., Jansen D.R. Methadone maintenance: Some client opinions. American Journal of Psychiatry 1975, 132:623-626.
9. Brown R., Balousek S., Mundt M., Fleming M. Methadone maintenance and male sexual dysfunction. Journal of Addictive Diseases 2005, 24:91-106.
10. Bruera E., Macmillan K., Selmser P., MacDonald R.N. Decreased local toxicity with subcutaneous diamorphine (heroin): A preliminary report. Pain 1990, 43:91-94.
11. Bundesrat Botschaft zum Bundesgesetz über die Verlängerung des Bundesbeschlusses über die ärztliche Verschreibung von Heroin Available at. http://www.admin.ch/ch/d/ff/2002/5839.pdf.
12. Caplehorn J.R., Irwig L., Saunders J.B. Physicians' attitudes and retention of patients in their methadone maintenance programs. Substance Use and Misuse 1996, 31:663-677.
13. Clark J.D., Elliott J. A case of a methadone-induced movement disorder. The Clinical Journal of Pain 2001, 17:375-377.
14. D'Aunno T., Pollack H.A. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. JAMA 2002, 288:850-856.
15. D'Aunno T., Vaugh T.E. Variations in methadone treatment practices. Results from national study. JAMA 1992, 267:253-258.
16. Davoli M., Perucci C.A., Forastiere F., Doyle P., Rapiti E., Zaccarelli M., Abeni D.D. Risk factors for overdose mortality: A case-control study within a cohort of intravenous drug users. International Journal of Epidemiology 1993, 22:273-277.
17. De Amici D., Klersy C., Ramajoli F., Brustia L., Politi P. Impact of the Hawthorne effect in a longitudinal clinical study: The case of anesthesia. Controlled Clinical Trials 2000, 21:103-114.
18. Dürsteler-MacFarland K.M., Stohler R., Moldovanyi A., Rey S., Basdekis R., Gschwend P., Eschmann S., Rehm J. Complaints of heroin-maintained patients: A survey of symptoms ascribed to diacetylmorphine. Drug and Alcohol Dependence 2006, 81:231-239.
19. Dürsteler-MacFarland K.M., Störmer R., Seifritz E., Hug I., Müller-Spahn F., Ladewig D., Stohler R. Opioid-associated effects on oxygen saturation in humans. Addiction 2000, 95:285-287.
20. Ehret G.B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B., Piguet V., Musset T., Gaspoz J.M., Perrier A., Dayer P., Desmeules J.A. Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Archives of Internal Medicine 2006, 166:1280-1287.
21. Florez J., Mediavilla A. Respiratory and cardiovascular effects of met-enkephalin applied to the ventral surface of the brain stem. Brain Research 1978, 138:585-590.
22. FOPH-Federal Office of Public Health Heroin-assisted treatment/treatment with diacetylmorphine (HAT) in 2006 Available at. http://www.bag.admin.ch/themen/drogen/00042/00629/00798/01191/index.html?lang=en.
23. French M.T., Zarkin G.A., Hubbard R.L., Rachal J.V. The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity. American Journal of Drug and Alcohol Abuse 1993, 19:19-33.
24. Goldsmith D.S., Hunt D.E., Lipton D.S., Strug D.L. Methadone folklore: Beliefs about side effects and their impact on treatment. Human Organization 1984, 43:330-340.
25. Graham C.H., Meechan J.G. Dental management of patients taking methadone. Dental Update 2005, 32:477-485.
26. Grönbladh L., Ohlund L.S., Gunne L.M. Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatrica Scandinavia 1990, 83:223-227.
27. Gupta R., Haydock T. Severe hypercapnia caused by acute heroin overdose. Annals of Emergency Medicine 2004, 43:665-666.
28. Hartel D.M., Schoenbaum E.E. Methadone treatment protects against HIV infection: Two decades of experience in the Bronx, New York City. Journal of Public Health Reports 1998, 113(Suppl. 1):107-115.
29. Hubbard R.L., Marsden M.E., Rachal J.V., Harwood H.J., Cavangh E.R., Ginzburg H.M. Drug abuse treatment: A national study of effectiveness 1989, University of North Carolina Press, Carey.
30. Hunt D.E., Lipton D.S., Goldsmith D.S., Strug D.L., Spunt B. "It takes your heart": The image of methadone maintenance in the addict world and its effect on recruitment into treatment. International Journal of the Addictions 1985, 20:1751-1771.
31. Judson B.A., Goldstein A. Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers. Drug and Alcohol Dependence 1982, 10:269-282.
32. Kayman D.J., Goldstein M.F., Deren S., Rosenblum A. Predicting treatment retention with a brief "Opinions About Methadone" scale. Journal of Psychoactive Drugs 2006, 38:93-100.
33. Krantz M.J., Lowery C.M., Martell B.A., Gourevitch M.N., Arnsten J.H. Effects of methadone on QT-interval dispersion. Pharmacotherapy 2005, 25:1523-1529.
34. Kreek M.J., Hartman N. Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids, and toxicity. Annals of the New York Acadademy of Science 1982, 398:151-172.
35. Kreek M.J., Vocci F.J. History and current status of opioid maintenance treatments: Blending conference session. Journal of Substance Abuse Treatment 2002, 23:93-105.
36. Longwell B., Kestler R.J., Cox T.J. Side effects in methadone patients: A survey of self-reported complaints. The International Journal of the Addictions 1979, 14:485-494.
37. Magura S., Rosenblum A. Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. The Mount Sinai Journal of Medicine 2001, 68:62-74.
38. Martin J.E., Inglis J. Pain tolerance and narcotic addiction. The Brithish Journal of Social and Clinical Psychology 1965, 4:224-229.
39. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003, (2):CD002209.
40. Mercadante S., Villari P., Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Supportive Care in Cancer 2001, 9:205-206.
41. Mintz J., O'Hare K., O'Brien C.P., Goldschmidt J. Sexual problems of heroin addicts. Archives of General Psychiatry 1974, 31:700-703.
42. Moldovanyi A., Ladewig D., Affentranger P., Natsch C., Stohler R. Morphine maintenance treatment of opioid-dependent out-patients. European Addiction Research 1996, 2:208-212.
43. Morabia A., Fabre J., Chee E., Zeger S., Orsat E., Robert A. Diet and opiate addiction: A quantitative assessment of the diet of non-institutionalized opiate addicts. British Journal of Addiction 1989, 84:173-180.
44. Nolan L.J., Scagnelli L.M. Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Substance Use and Misuse 2007, 42:1555-1566.
45. Nordt C., Stohler R. Incidence of heroin use in Zurich, Switzerland: A treatment case register analysis. The Lancet 2006, 367:1830-1834.
46. Novick D.M., Richman B.L., Friedman J.M., Friedman J.E., Fried C., Wilson J.P., Townley A., Kreek M.J. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug and Alcohol Dependence 1993, 33:235-245.
47. Peles E., Bodner G., Kreek M.J., Rados V., Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: A cross-sectional study. Addiction 2007, 102:289-300.
48. Peles E., Schreiber S., Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug and Alcohol Dependence 2006, 82:103-110.
49. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
50. Rehm J., Gschwend P., Steffen T., Gutzwiller F., Dobler-Mikola A., Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. The Lancet 2001, 358:1417-1423.
51. Rook E.J., van Zanten A.P., Van den Brink W., van Ree J.M., Beijnen J.H. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin. Drug and Alcohol Dependence 2006, 85:185-190.
52. Rosenblum A., Magura S., Joseph H. Ambivalence toward methadone treatment among intravenous drug users. Journal of Psychoactive Drugs 1991, 23:21-27.
53. Santiago T.V., Pugliese A.C., Edelman N.H. Control of breathing during methadone addiction. The American Journal of Medicine 1977, 62:347-354.
54. Sarhill N., Davis M.P., Walsh D., Nouneh C. Methadone-induced myoclonus in advanced cancer. The American Journal of Hospice and Palliative Care 2001, 18:51-53.
55. Schmittner J., Schroeder J.R., Epstein D.H., Preston K.L. Menstrual cycle length during methadone maintenance. Addiction 2005, 100:829-836.
56. Sepelloni G., Carrierei M.P., Rezza G., Morganti S., Gomma M., Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: A nested case-control study. AIDS Care 1994, 6:215-220.
57. Simpson D.D. The relation of time spent in drug abuse treatment to posttreatment outcome. American Journal of Psychiatry 1979, 136:1449-1453.
58. Simpson D.D., Savage L.J., Lloyd M.R. Follow-up evaluation of treatment of drug abuse during 1969 to 1972. Archives of General Psychiatry 1979, 36:772-780.
59. Clinical recommendations for substitution-assisted treatment in opioid dependence SSAM?Swiss Society of Addiction Medicine, Available at. http://www.ssam.ch/SSAM/en/Clinical%20Recommendations.
60. Stancliff S., Myers J.E., Steiner S., Drucker E. Beliefs about methadone in an inner-city methadone clinic. Journal of Urban Health 2002, 79:571-578.
61. Stoermer R., Drewe J., Dürsteler-MacFarland K., Ladewig D., Hock C., Müller-Spahn F., Stohler R., Mager R. Safety of injectable opioid treatment in addiction: A controlled clinical trial. Biological Psychiatry 2003, 54:854-861.
62. Strike C.J., Gnam W., Urbanoski K., Fischer B., Marsh D.C., Millson M. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addictive Behaviors 2005, 30:1025-1028.
63. Uchtenhagen A., Gutzwiller F., Dobler-Mikola A., Steffen T. Programme for a medical prescription of narcotics: A synthesis of results. European Addiction Research 1997, 3:160-163.
64. Uehlinger C., Hauser C. Allergic reactions from injectable methadone. American Journal of Psychiatry 1999, 156:973.
65. WHO The ICD-10 Classification of Mental and Behavioural Disorders, Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization, Geneva.
66. Ward J., Hall W., Mattick R.P. Role of maintenance treatment in opioid dependence. The Lancet 1999, 353:221-226.
67. Warner L.A., Kessler R.C., Hughes M., Anthony J.C., Nelson C.B. Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1995, 52:219-229.
68. Zador D., Lyons Wall P.M., Webster I. High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. Addiction 1996, 91:1053-1061.
69. Zule W.A., Desmond D.P. Attitudes toward methadone maintenance: Implications for HIV prevention. Journal of Psychoactive Drugs 1998, 30:89-97.